An Open-Label Comparative Pilot Study of Oral Voriconazole and Itraconazole for Long-Term Treatment of Paracoccidioidomycosis | Zendy

Flávio Queiroz Telles | Zendy; Luciano Z. Goldani | Zendy; Haran T. Schlamm | Zendy; J. M. Goodrich | Zendy; A. E. Ingroff | Zendy; Maria Aparecida ShikanaiYasuda | Zendy

Open Access

An Open-Label Comparative Pilot Study of Oral Voriconazole and Itraconazole for Long-Term Treatment of Paracoccidioidomycosis

Author(s) -

Flávio Queiroz Telles,

Luciano Z. Goldani,

Haran T. Schlamm,

J. M. Goodrich,

A. E. Ingroff,

Maria Aparecida ShikanaiYasuda

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/522973

Subject(s) - itraconazole , paracoccidioidomycosis , voriconazole , medicine , tolerability , gold standard (test) , open label , clinical trial , dermatology , adverse effect , antifungal , immunology

In previous studies, itraconazole was revealed to be an effective therapy and was considered to be the gold standard treatment for mild-to-moderate acute and chronic clinical forms of paracoccidioidomycosis. A pilot study was conducted to investigate the efficacy, safety, and tolerability of voriconazole for the long-term treatment of acute or chronic paracoccidioidomycosis, with itraconazole as the control treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research